CIK 0001740279 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 825462585
- Phone
- (646) 600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-19 | Brandt Peter C. Director | Grant or award · Stock Option (right to buy) | +49,490 | 49,490 | ||
| 2024-12-19 | Roemer Alan S. Director | Grant or award · Stock Option (right to buy) | +93,242 | 93,242 | ||
| 2024-12-19 | McCall Patrick CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +290,085 | 290,085 | ||
| 2024-12-19 | Lamb Lawrence EVP and CSO | Grant or award · Employee Stock Option (right to buy) | +286,899 | 286,899 | ||
| 2024-12-19 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +302,839 | 302,839 | ||
| 2024-12-19 | Ho William Tai-Wei PRESIDENT AND CEO | Grant or award · Employee Stock Option (right to buy) | +1,188,282 | 1,188,282 | ||
| 2024-10-04 | Kreis Leslie W. 10% owner | Purchase · Pre-Funded Warrants | +709,040 | 1,283,281 | ||
| 2024-10-04 | Kreis Leslie W. 10% owner | Purchase · Series C Warrant | +709,040 | 709,040 | ||
| 2024-10-04 | Kreis Leslie W. 10% owner | Returned to the company · Series A Warrant | +574,241 | 0 | ||
| 2024-10-04 | Kreis Leslie W. 10% owner | Grant or award · Series A Warrant | +574,241 | 574,241 | ||
| 2024-10-04 | Fletcher Aaron G.L. 10% owner | Purchase · Pre-Funded Warrants | +709,040 | 1,283,281 | ||
| 2024-10-04 | Fletcher Aaron G.L. 10% owner | Purchase · Series C Warrant | +709,040 | 709,040 | ||
| 2024-10-04 | Fletcher Aaron G.L. 10% owner | Returned to the company · Series A Warrant | +574,241 | 0 | ||
| 2024-10-04 | Fletcher Aaron G.L. 10% owner | Grant or award · Series A Warrant | +574,241 | 574,241 | ||
| 2024-10-04 | FAIRBAIRN EMILY Director | Purchase · Series C Warrants (right to buy) | +3,038,743 | 3,038,743 | ||
| 2024-10-04 | FAIRBAIRN EMILY Director | Purchase · Pre-Funded Warrants (right to buy) | +3,038,743 | 3,038,743 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award | +25,316 | 42,874 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Returned to the company · Series A Warrants (right to buy) | −12,295 | 0 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award · Series A Warrants (right to buy) | +12,295 | 12,295 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award · Series C Warrants (right to buy) | +25,316 | 25,316 |
Page 5 of 9 · 179 trades